Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.

Rifaat SafadiMarius BraunAdi FrancisYael MilgromMuhammad MassarwaDavid HakimianWadi HazouAssaf IssacharZivit HarpazMotti FarbsteinInbal ItzhakNaama Lev-CohainAvital Bareket-SamishMichael H SilvermanPnina Fishman

Published in: Alimentary pharmacology & therapeutics (2021)

A3AR is a valid target; namodenoson 25 mg b.d. was safe and demonstrated efficacy signals (ClinicalTrials.gov #NCT02927314).

Keyphrases

clinical trial
double blind
placebo controlled
study protocol
open label
phase ii
phase iii
liver fibrosis
randomized controlled trial